ALPHA-BLUE-OCEAN
25.4.2024 16:01:28 CEST | Business Wire | Press release
Environmental Performance Financing (EPF), a subsidiary of the Alpha Blue Ocean group, is proud to announce its collaboration with Europlasma (ALEUP:FP), a leader in depollution, material recovery, and decarbonation solutions, for the establishment of a bond financing arrangement.
This financing aims to support the Group's growth and development, particularly in key initiatives such as:
- The acquisition of MG-Valdunes: Europlasma has obtained the green light for the acquisition of MG-Valdunes' business assets, a crucial step towards strengthening industrial sovereignty and relaunching Valdunes' historic activities.
- The development of the Forges de Tarbes: Funds will also be allocated to increasing the production capacities of the Forges de Tarbes, which are facing growing demand, particularly in the defense sector.
- The continued development of historical activities: A significant portion of the funds will be dedicated to the ongoing development of depollution, decarbonation, and hazardous waste recovery activities, a domain in which Europlasma has excelled for years.
This partnership will strengthen Europlasma's market position while contributing to the achievement of essential environmental objectives.
This collaboration illustrates ABO Group's commitment to financing innovative and sustainable environmental projects.
Pierre Vannineuse, CIO and Founder of Alpha Blue Ocean: "We are delighted to announce the renewal of our partnership with Europlasma for a 7th significant financing contract. This long-standing collaboration represents our commitment to supporting innovative and sustainable environmental projects over the long term. After seven years of fruitful collaboration with Europlasma, this new contract once again illustrates the success of our joint efforts. Europlasma embodies a French industrial flagship and an unparalleled global reference in its sector. We are all fully committed to establishing this collaboration on a lasting basis and to maintain the positive momentum that has been built in recent years.”
Jérôme Garnache-Creuillot, CEO Europlasma :
"I would like to thank the ABO team who continues to financially support the significant growth of the Europlasma Group. Without this support, the rescue of Forges de Tarbes in 2021 would have been impossible. Today, their expertise is preserved, and they contribute more each day to the production of large caliber shells. ABO’s loyal support, as well as that of the Economic and Social Development Fund and local authorities, enables Europlasma to save Valdunes, the last French manufacturer of train wheels and axles. Thus, thanks to this funding, another French expertise, once again strategic, is preserved."
About Alpha Blue Ocean:
Established in 2017, Alpha Blue Ocean is a pioneering and leading player in alternative finance in Europe and worldwide, particularly in the field of medical innovation. In 5 years, the group founded by Pierre Vannineuse has executed over 2 billion euros in financial commitments, 60% of which are in the Healthcare & Innovation sectors.
About EUROPLASMA:
Europlasma is a French group with an international presence, dedicated to designing and developing expertise for the benefit of humanity and the environment. A specialist in depollution, its innovative solutions are aimed at the treatment and valorization of hazardous waste using its proprietary technology, the plasma torch, as well as applications for industries concerned with reducing their environmental footprint, through the substitution of fossil fuels or recycling in a circular economy logic.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240425028344/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom